Summarized by Masters of Longevity from PR Newswire.
A generative AI-discovered small molecule has advanced as the lead into a multicenter Phase III trial testing efficacy and safety over 52 weeks in idiopathic pulmonary fibrosis patients.
Key Takeaways
- Insilico dosed the first patient in a randomized double-blind placebo-controlled Phase III trial testing Rentosertib for IPF.
- Phase III will assess once-daily Rentosertib over 52 weeks following promising Phase IIa lung function improvements.
- Insilico reported strong 2026 commercial momentum with $106 million H1 revenue and $7.3 billion in 2026 announced contract value.
